Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.

Xu, Zhenhua; Davis, Hugh M; Zhou, Honghui

Xu, Zhenhua; Davis, Hugh M; Zhou, Honghui.

Affiliation

Xu Z; Janssen Research and Development, LLC., Spring House, PA, USA.

J Clin Pharmacol ; 55 Suppl 3: S60-74, 2015 Mar.

Article in En | MEDLINE | ID: mdl-25707965

Subject(s)

Antibodies, Monoclonal; Biological Products; Immunologic Factors; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/pharmacokinetics; Antibodies, Monoclonal/therapeutic use; Biological Products/adverse effects; Biological Products/pharmacokinetics; Biological Products/therapeutic use; Drug Interactions; Drug Therapy, Combination; Humans; Immunologic Factors/adverse effects; Immunologic Factors/pharmacokinetics; Immunologic Factors/therapeutic use; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Tumor Necrosis Factor-alpha/immunology

Key words

6-mercaptopurine; Crohn's disease; azathioprine; biologic therapy; drug-drug interaction; immunogenicity; immunomodulator; immunosuppression; inflammatory disease; metabolism; methotrexate; monoclonal antibody; pharmacokinetics; rheumatoid arthritis; safety; tumor necrosis factor blocker

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Immunologic Factors / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Clin Pharmacol Year: 2015 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google